

Evaluation of Chlorogenic Acid in Parkinson's Disease Model: An In-vitro Study in 6-OHDA Induced SH-SY5Y Cell Line

SUNPRAKATHI ALWARSAMY PERUMALSAMY¹, KRANTHI KARUNAI KADAL²,
GOWRI VISWANATHAN³, KAVITHA RAMASAMY⁴



ABSTRACT

Introduction: Parkinson's Disease (PD) is the most common neurodegenerative movement disorder. Mitochondrial dysfunction is a key pathological driver of PD. Pharmacological agents used in PD are not disease-modifying therapies and do not influence mitochondrial activity. Diets rich in polyphenols have been shown to prevent pathologies associated with ageing.

Aim: To evaluate Chlorogenic Acid (CGA), a phenolic acid, for its neuroprotective effect against PD in a 6-Hydroxydopamine (6-OHDA) induced SH-SY5Y cell line using in-vitro assays.

Materials and Methods: An in-vitro study was conducted at the Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India, from September 2023 to November 2023. The human neuroblastoma cell line SH-SY5Y was induced using 6-OHDA. The activity of CGA against cytotoxicity in the 6-OHDA induced SH-SY5Y cell line was evaluated using the MTT assay with

different concentrations (3.125 μ M, 6.25 μ M, 12.5 μ M, 25 μ M and 50 μ M). Mitochondrial Membrane Potential (MMP) was evaluated using flow cytometry and antiapoptotic activity was assessed using Cytochrome C immunofluorescence by fluorescence microscopy. One-way Analysis of Variance (ANOVA) with Tukey's posthoc analysis was used to identify statistical significance at p-value <0.05.

Results: The CGA exhibited the maximum protective concentration on the 6-OHDA induced SH-SY5Y cell line at 25 μ M, with a restoration of cell viability of 43.04%. CGA also improved the mitochondrial membrane potential and reduced the levels of cytochrome C release thus maintaining the mitochondrial membrane integrity.

Conclusion: The findings provide evidence that CGA may exert an anti-PD effect through its action on mitochondrial dysfunction and the release of pro-apoptotic factors. The observed action on neuronal cells makes CGA a potential candidate for anti-PD treatment.

Keywords: 6-Hydroxydopamine, Cytochrome C, Mitochondrial membrane potential

INTRODUCTION

Parkinson's disease is the most prevalent neurodegenerative movement disorder, occurring in individuals aged between 55 and 65 years, with a mean age of onset around 60 years [1,2]. The prevalence of PD is approximately 5 million and is expected to double by 2030 [1,3]. The early, substantial loss of dopamine in the substantia nigra pars compacta (SNpc) and the widespread presence of the intracellular protein alpha-synuclein (aSyn) are the hallmarks of PD. A deficiency of dopamine in the basal ganglia causes characteristic motor symptoms of PD, such as tremor, bradykinesia, postural instability and rigidity. Non motor components, including cognitive impairment, olfactory dysfunction, psychiatric symptoms, sleep disorders, autonomic dysfunction, pain and fatigue, may appear more than a decade before motor symptoms [4]. As the disease progresses, these non motor symptoms become increasingly challenging [5]. Despite significant progress in both medical and surgical treatments for PD, a definitive disease-modifying therapy is still unavailable [1,3,5,6].

Mitochondria, a vital and dynamic organelles that provide energy for the cell, have long been implicated in the pathogenesis of PD [7,8]. Mitochondrial dysfunction is a central hallmark of PD. Evidence from various studies underscores mitochondrial dysfunction as a significant driver of both idiopathic and familial PD. Key attributes of the pathogenesis include impairment of mitochondrial Complex I (CI), disturbed mitochondrial quality control mechanisms, increased oxidative stress and bioenergetic deficiency [8]. CI deficiency in PD may be associated with the primary disease process [3,9]. However, the drugs commonly used to manage PD are not known to influence complex I activity [10].

6-Hydroxydopamine (6-OHDA) is a widely used neurotoxin that serves as an inducing agent in PD models. 6-OHDA enters dopaminergic and noradrenergic neurons via specific transporters, accumulates in the cytosol and induces oxidative stress [11,12]. It also causes mitochondrial complex I inhibition [13], reactive oxygen species production, protein misfolding and apoptosis, ultimately leading to the degeneration of dopaminergic neurons [11,12].

Modelling PD is challenging with mature neurons due to their non dividing nature; therefore, immortalised cell lines have been established to serve as cell culture models [11,14]. The SH-SY5Y cell line, derived from human neuroblastoma, is the most commonly used immortalised cell line in PD research [15]. This subline was established using bone marrow from a four-year-old female with metastatic neuroblastoma [16]. SH-SY5Y cells are widely employed to model PD and evaluate the neuroprotective role of various biologically active compounds. These cells display characteristics similar to neurons found in the substantia nigra [6,11]. Additionally, they can be differentiated into a more mature dopaminergic phenotype for advanced studies. Together, these features make SH-SY5Y an effective in-vitro model for PD research [15].

In recent years, the study of natural products has garnered significant global attention, offering promising opportunities for therapeutic advancement in the treatment of PD. Studies have shown that both Mediterranean and Asian diets play a role in preventing various age-related diseases. Notably, the polyphenols present in these diets are strongly associated with a significant reduction in neurodegeneration [17]. One such polyphenol is CGA, predominantly found in coffee. Studies in in-vivo and in-vitro models have revealed that CGA exhibits strong antioxidant properties and

effectively alleviates oxidative stress across diverse disease models [18]. However, research on the influence of phenolic acids in PD and other neurodegenerative diseases remains scarce. The present study examined the potential benefits of CGA on SH-SY5Y cells injured by 6-OHDA and investigated its potential influence on complex I activity, aiming to uncover the underlying mechanisms of its neuroprotective action and its potential role in PD.

MATERIALS AND METHODS

The present in-vitro study was conducted in the Department of Pharmacology and Central Research Facility at the Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, India, from September 2023 to November 2023, after obtaining ethical approval (CSP-MED/23/SEP/92/212).

Study Procedure

Chemicals: Dulbecco's Phosphate Buffered Saline (DPBS), diphenyl tetrazolium bromide (MTT) dye, Foetal Bovine Serum (FBS) and Dulbecco's Modified Eagle Medium (DMEM) - High Glucose, were obtained from HiMedia (Mumbai, India). Dimethyl Sulfoxide (DMSO), Anti-Cytochrome C primary antibody, 5, 5', 6, 6'-tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1), 4', 6-Diamidino-2-Phenylindole Dihydrochloride (DAPI) dye and 6-hydroxydopamine (6-OHDA) were procured from Sigma Aldrich (USA). CGA was obtained from Sisco Research Laboratories, India.

Cell culture: The human bone marrow neuroblastoma cell line SH-SY5Y, purchased from the National Centre for Cell Science, India, was maintained in DMEM high glucose media supplemented with 10% FBS and 1% antibiotic-antimycotic solution. The cells were incubated in an atmosphere of 18-20% O₂ and 5% CO₂ in a CO₂ incubator at 37°C and sub-cultured every third day [19].

Treatment of cells: A 96-well plate was seeded with approximately 20,000 cells. After a 24-hour incubation at 37°C, the spent media was aspirated. Following this, the cells were treated for an additional 24 hours with various concentrations of CGA.

MTT assay: To determine how CGA affected the viability of 6-OHDA induced SH-SY5Y cells, approximately 20,000 cells were cultured for 24 hours in a 96-well plate. The SH-SY5Y cells were subsequently exposed to multiple doses of CGA (3.125, 6.25, 12.5, 25 and 50 µM) for a period of one hour and then treated with 100 µM of 6-OHDA for 24 hours. One group was treated with only 100 µM of 6-OHDA, while the untreated group was not exposed to either 6-OHDA or CGA. After treatment, the cells were subjected to MTT (0.5 mg/mL in DMEM) for one hour in a CO₂ incubator at 37°C to evaluate cell viability. Following the removal of the MTT solution, the dye crystals were dissolved in 100 µL of DMSO and measured at 570 nm using an ELISA reader [20]. The cell viability percentage was estimated using the following equation based on the observed absorbance values.


$$\% \text{ cell viability} = \frac{\text{Mean absorbance value of treated cells}}{\text{Mean absorbance value of untreated cells}} \times 100 \quad [21]$$

Determination of mitochondrial membrane potential: The MMP/ΔΨ_m is pivotal in sustaining the electrochemical gradient and its impairment may lead to neuronal cell death [22]. JC-1, a lipophilic fluorochrome, is employed to assess the status of ΔΨ_m. JC-1 is the first J-aggregate-forming cationic dye and is responsive to ΔΨ_m. In functioning mitochondria, JC-1 aggregates and emits red fluorescence. Conversely, in dead cells with low MMP, the dye remains in a monomeric form, emitting green fluorescence.

Post-treatment with CGA, the 6-OHDA induced SH-SY5Y cells were harvested and centrifuged for five minutes in polystyrene tubes. After washing with PBS, each pellet was incubated for 10-15 minutes with JC-1 working solution (0.5 mL). The supernatant was removed after two washes with assay buffer and the cells were

resuspended in 0.5 mL of assay buffer. Flow cytometric analysis was performed using FL1 and FL2 channels, with Fluorescence-Activated Cell Sorting Diva (FACSDiva) software utilised for histogram generation [23].

Cytochrome C immunofluorescence: Cytochrome C immunofluorescence serves as a method to qualitatively measure apoptotic cells, as its release into the cytoplasm marks a pro-apoptotic event [24]. Following treatment with CGA, cells were harvested in 2 mL Eppendorf tubes and treated with fluorescence-labelled cytochrome C antibody for 10 minutes. After removal of the staining solution and excess antibody, the cells were counterstained with DAPI. Subsequently, 50 µL of the cell suspension was spread on a glass slide with mounting medium and observed under fluorescence using the LSM 880 live cell imaging confocal system (Carl Zeiss). The images were combined in ImageJ Software v1.48 using Regions of Interest (ROI)-based Intensity Quantification to determine the Mean Fluorescence Intensity [25]. [Table/Fig-1] depicts an overview of the study flowchart.



[Table/Fig-1]: Overview of the study flowchart.


STATISTICAL ANALYSIS

The data was expressed as Mean±Standard Deviation (SD). Statistical analyses were conducted using GraphPad Prism 8. To determine the significance of differences, a one-way ANOVA with Tukey's posthoc test was utilised, with significance considered at a p-value of less than 0.05. Each experiment was performed in triplicate.

RESULTS


Effect of CGA on Cell Viability

To analyse the CGA-mediated effect on cell viability, an MTT assay was performed on the 6-OHDA-induced SH-SY5Y cell line. As illustrated in [Table/Fig-2a-c], treatment with 6-OHDA (100 µM) led to a substantial loss of cell viability (13.10±0.74%) compared to the control. In contrast, treatment with CGA restored cell viability, with a maximum restoration percentage of (43.04±0.19%) observed at 25 µM (p<0.001). Cell morphology, visualised under a bright field microscope, revealed that treatment with various concentrations of CGA salvaged cell viability compared to 6-OHDA [Table/Fig-2b].



Effect of CGA on Mitochondrial Membrane Potential

As depicted in [Table/Fig-3a,c], exposure to 6-OHDA depolarised the mitochondria in neuronal cells, resulting in mitochondrial damage (96.65±1.06%). However, treatment with CGA preserved healthy mitochondria in the cells against 6-OHDA toxicity (34.74±0.41%) (p<0.001). Depolarised $\Delta\Psi_m$ is indicated by JC-1 fluorescing in the FL-1 channel while not exhibiting fluorescence in the FL-2 channel. The upward shift in cell population towards FL-2 indicates improved membrane polarisation following treatment with CGA [Table/Fig-3b].




Effect of CGA on Cytochrome C Immunofluorescence

Exposure to 6-OHDA increased cytochrome C release in neuronal cells, as evidenced by the diffuse red staining and nuclear changes in blue. In contrast, treatment with CGA restored nuclear morphology and mitochondrial integrity, as indicated by the punctate red staining and intact blue nuclei in the presence of 6-OHDA toxicity [Table/Fig-4a,c]. The relative mean fluorescence intensity of the 6-OHDA group was 5.9±0.2; however, when treated with CGA, the intensity reduced to 2.81±0.19.

DISCUSSION

Over the years, the concept of disease-modifying treatment has been widely explored in neurodegenerative disorders such as PD [26]. Various mechanisms attributed to the pathophysiology of PD include α -synuclein aggregation, oxidative stress, mitochondrial impairment, dysfunction in cellular clearance pathways, autophagy, alterations in the microbiome and a number of genetic contributors [2]. Developing disease-modifying therapies for PD has proven to be exceptionally challenging due to these complex underlying mechanisms, making a drug that addresses all these domains crucial for effective management.


The CGA is a phenolic acid found abundantly in coffee [18]. Multiple studies conducted on human cell lines and animal models have demonstrated the protective function of CGA in combating oxidative stress in brain tissue [27-29]. CGA has the potential to scavenge superoxide radicals ($\bullet O_2^-$), 2,2'-azino-bis (3-ethylbenothiazoline-6-sulfonic acid) cation radicals (ABTS \bullet^+), hydroxyl radicals ($\bullet OH$) and 2,2-diphenyl-1-picrylhydrazyl radicals (DPPH \bullet) [18,25]. In a study conducted on the 6-OHDA-treated SH-SY5Y cell line, CGA alleviated ROS production and endoplasmic reticulum stress and restored 6-OHDA-induced cytotoxicity. It also reversed motor deficits in 6-OHDA lesioned rats and enhanced antioxidant enzyme activity in the striatum of the rat brain [30]. Moreover, studies have revealed that CGA possesses an antiapoptotic effect as well [27,31].



In a study conducted by Teraoka M et al., on α -synuclein-related cytotoxicity in catecholaminergic PC12 cells, CGA demonstrated an inhibitory effect against dopamine oxidation, the interaction of oxidised dopamine with α -synuclein, as well as α -synuclein oligomerisation [32]. CGA also inhibited the accumulation of α -synuclein and the degeneration of dopaminergic neurons, improving motor ability via autophagy induction in *Caenorhabditis elegans* [33]. Furthermore, CGA has been shown to modulate intestinal inflammation, thus regulating the gut-brain axis [34].

In the present study, the MTT assay revealed that CGA reduced the cytotoxicity caused by 6-OHDA and restored the viability of SH-SY5Y cells. The effects of reactive oxygen species and mitochondrial membrane impairment are well-documented pathophysiological mechanisms in PD. The function of the mitochondrial Permeability Transition Pore (mPTP), located in the inner mitochondrial membrane, is regulated by changes in MMP and is generally closed. However, due to the charge difference between the mitochondrial matrix and the cytosol, mitochondrial

membrane depolarisation can lead to the prolonged opening of the mPTP, resulting in the release of cytochrome C, a pro-apoptotic factor. This release triggers the activation of the caspase cascade, ultimately leading to cell death [24]. In the present study, CGA at a dose of 25 μ M alleviated mitochondrial membrane depolarisation and reduced cytochrome C release by maintaining mitochondrial membrane integrity [Table/Fig-5].



Research suggests that CGA and its metabolites can traverse the Blood-Brain Barrier (BBB), potentially exerting neuroprotective effects on brain tissue. A study conducted by Cropley V et al., on a healthy older population, who were administered decaffeinated coffee enriched with CGA, showed improvements in mood and cognition [35]. However, these findings were not consistently reproducible in other studies [27,36]. In research conducted by Lardeau A and Poquet L using an in-vitro BBB model, very low rates of BBB permeation were observed, leading to the conclusion that CGA cannot be considered for its direct action on the central nervous system [37]. A brain distribution and plasma pharmacokinetic study comparing intravenous and intranasal CGA in Charles-Foster rats concluded that intranasal CGA provided rapid absorption, increased penetration and higher drug targeting efficiency compared to the intravenous route, offering a promising approach for treating neurodegenerative disorders [38].

The findings of the present study indicate that CGA reduced the cytotoxicity caused by 6-OHDA and curtailed cytochrome C release by maintaining mitochondrial membrane integrity in the SH-SY5Y cell line, owing to its antioxidant effects.

Limitation(s)

The assays used in the present study focus primarily on mitochondrial dysfunction. However, further studies are crucial to assess the effects of CGA on various factors and genes implicated in the pathophysiology of PD. Additionally, in-vivo studies involving appropriate animal models are necessary to validate these findings.

CONCLUSION(S)

The results of the present study conclude that CGA, at a dose of 25 μ M, protected the SH-SY5Y cell line from 6-OHDA toxicity by mitigating the effects of complex I impairment. This was achieved by improving cell viability, maintaining MMP and minimising the release of cytochrome C. The findings of the present study contribute to the holistic potential of CGA as a viable candidate for the management of PD.

Acknowledgement

The authors would like to express their heartfelt gratitude to the Department of Pharmacology, Sri Ramachandra Medical College and Research Institute for providing the facilities to complete the present research.

Authors' contribution: All authors contributed equally to this work. The authors confirm their contribution to the paper as follows: SAP- study conception and design; KKK-Data analysis and interpretation of results; GV-Draft preparation and KR- Manuscript guidance. All authors reviewed the results and approved the final version of the manuscript.

REFERENCES

- [1] Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's principles of internal medicine (-2022). McGraw Hill; 2022.
- [2] Balestrino R, Schapira AHV. Parkinson disease. *Eur J Neurol*. 2020;27(1):27-42. Doi: 10.1111/ene.14108. Epub 2019 Nov 27. PMID: 31631455.
- [3] Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. *Neurobiol Dis*. 2013;51:35-42. Doi: 10.1016/j.nbd.2012.10.011. Epub 2012 Oct 12. PMID: 23064436; PMCID: PMC3565564.
- [4] Kalia LV, Lang AE. Parkinson's disease. *Lancet*. 2015;386(9996):896-912. Doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19. PMID: 25904081.
- [5] Radhakrishnan DM, Goyal V. Parkinson's disease: A review. *Neurol India*. 2018;66(Supplement):S26-S35. Doi: 10.4103/0028-3886.226451. PMID: 29503325.
- [6] Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson's disease research: A systematic review. *Mol Neurodegener*. 2017;12(1):10. Doi: 10.1186/s13024-017-0149-0. PMID: 28118852; PMCID: PMC5259880.
- [7] Gao XY, Yang T, Gu Y, Sun XH. Mitochondrial dysfunction in Parkinson's disease: From mechanistic insights to therapy. *Front Aging Neurosci*. 2022;14:885500. Doi: 10.3389/fnagi.2022.885500. PMID: 35795234; PMCID: PMC9250984.
- [8] Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson's disease- a key disease hallmark with therapeutic potential. *Mol Neurodegener*. 2023;18(1):83. Doi: 10.1186/s13024-023-00676-7. PMID: 37951933; PMCID: PMC10640762.
- [9] Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. *J Neurochem*. 1990;54(3):823-27. Doi: 10.1111/j.1471-4159.1990.tb02325.x. PMID: 2154550.
- [10] Schapira AH. Mitochondrial dysfunction in Parkinson's disease. *Cell Death Differ*. 2007;14(7):1261-66. Doi: 10.1038/sj.cdd.4402160. Epub 2007 Apr 27. PMID: 17464321.
- [11] Turan D, Abdik H, Sahin F, Avşar Abdik E. Evaluation of the neuroprotective potential of caffeic acid phenethyl ester in a cellular model of Parkinson's disease. *Eur J Pharmacol*. 2020;883:173342. Doi: 10.1016/j.ejphar.2020.173342. Epub 2020 Jul 4. PMID: 32634439.
- [12] Kesh S, Kannan RR, Balakrishnan A. Naringenin alleviates 6-hydroxydopamine induced Parkinsonism in SHSY5Y cells and zebrafish model. *Comp Biochem Physiol C Toxicol Pharmacol*. 2021;239:108893. Doi: 10.1016/j.cbpc.2020.108893. Epub 2020 Sep 16. PMID: 32949818.
- [13] Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. *Eur J Pharmacol*. 1995;292(3-4):329-32. Doi: 10.1016/0926-6917(95)90040-3. PMID: 7796873.
- [14] Zeng X, Chen J, Deng X, Liu Y, Rao MS, Cadet JL, et al. An in-vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP+ toxicity and GDNF neuroprotection. *Neuropsychopharmacology*. 2006;31(12):2708-15. Doi: 10.1038/sj.npp.1301125. PMID: 17109014; PMCID: PMC1852423.
- [15] Iloghen OC, Ceafalan LC, Popescu BO. SH-SY5Y cell line In-vitro models for Parkinson disease research-old practice for new trends. *J Integr Neurosci*. 2023;22(1):20. Doi: 10.31083/j.jin2201020. PMID: 36722247.
- [16] Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. *Cancer Res*. 1978;38(1 Pt 1):3751-57. PMID: 29704.
- [17] Aryal S, Skinner T, Bridges B, Weber JT. The pathology of Parkinson's disease and potential benefit of dietary polyphenols. *Molecules*. 2020;25(19):4382. Doi: 10.3390/molecules25194382. PMID: 32987656; PMCID: PMC7582699.
- [18] Liang N, Kitts DD. Role of chlorogenic acids in controlling oxidative and inflammatory stress conditions. *Nutrients*. 2015;8(1):16. Doi: 10.3390/nu8010016. PMID: 26712785; PMCID: PMC4728630.
- [19] Kaya ZB, Santiago-Padilla V, Lim M, Boschen SL, Atila P, McLean PJ. Optimizing SH-SY5Y cell culture: Exploring the beneficial effects of an alternative media supplement on cell proliferation and viability. *Sci Rep*. 2024;14(1):4775. Doi: 10.1038/s41598-024-55516-5. PMID: 38413790; PMCID: PMC10899233.
- [20] Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983;65(1-2):55-63. Doi: 10.1016/0022-1759(83)90303-4. PMID: 6606682.
- [21] Priya D, Hani U, Haider N, Talath S, Shanmugarajan D, Prabitha P, et al. Novel PPAR-γ agonists as potential neuroprotective agents against Alzheimer's disease: Rational design, synthesis, in silico evaluation, PPAR-γ binding assay and transactivation and expression studies. *RSC Adv*. 2024;14(45):33247-66. Doi: 10.1039/d4ra06330a. PMID: 39434987; PMCID: PMC11492828.
- [22] Ganjam GK, Bolte K, Matschke LA, Neiteimer S, Dolga AM, Höllerhage M, et al. Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons. *Cell Death Dis*. 2019;10(11):865. Doi: 10.1038/s41419-019-2091-2. PMID: 31727879; PMCID: PMC6856124.
- [23] Sivandzade F, Bhalaria A, Cucullo L. Analysis of the mitochondrial membrane potential using the cationic JC-1 dye as a sensitive fluorescent probe. *Bio Protoc*. 2019;9(1):e3128. Doi: 10.21769/BioProtoc.3128. PMID: 30687773; PMCID: PMC6343665.
- [24] Anis E, Zafeer MF, Firdaus F, Islam SN, Fatima M, Mobarak Hossain M. Evaluation of phytochemical potential of perillyl alcohol in an in-vitro Parkinson's disease model. *Drug Dev Res*. 2018;79(5):218-24. Doi: 10.1002/ddr.21436. PMID: 30188583.
- [25] Crowley LC, Marfell BJ, Scott AP, Waterhouse NJ. Analysis of Cytochrome c release by immunocytochemistry. *Cold Spring Harb Protoc*. 2016;2016(12). Doi: 10.1101/pdb.prot087338. PMID: 27934681.
- [26] Garcia Ruiz PJ, Luquin Pludo R, Martinez Castrillo JC. On disease modifying and neuroprotective treatments for Parkinson's disease: Physical exercise. *Front Neurol*. 2022;13:938686. Doi: 10.3389/fneur.2022.938686. PMID: 35911891; PMCID: PMC9331172.
- [27] Nabavi SF, Tajada S, Setzer WN, Gortzi O, Sureda A, Braidly N, et al. Chlorogenic acid and mental diseases: From chemistry to medicine. *Curr Neuropharmacol*. 2017;15(4):471-79. Doi: 10.2174/1570159X14666160325120625. PMID: 27012954; PMCID: PMC5543670.
- [28] Metwally DM, Alajmi RA, El-Khadragy MF, Yehia HM, AL-Megrin WA, Akabawy AM, et al. Chlorogenic acid confers robust neuroprotection against arsenite toxicity in mice by reversing oxidative stress, inflammation, and apoptosis. *J Funct Foods*. 2020;75:104202.
- [29] Zheng Y, Li L, Chen B, Fang Y, Lin W, Zhang T, et al. Chlorogenic acid exerts neuroprotective effect against hypoxia-ischemia brain injury in neonatal rats by activating Sirt1 to regulate the Nrf2-NF-κB signaling pathway. *Cell Commun Signal*. 2022;20(1):84. Doi: 10.1186/s12964-022-00860-0. PMID: 35689269; PMCID: PMC9185968.
- [30] Shan S, Tian L, Fang R. Chlorogenic acid exerts beneficial effects in 6-hydroxydopamine-induced neurotoxicity by inhibition of endoplasmic reticulum stress. *Med Sci Monit*. 2019;25:453-59. Doi: 10.12659/MSM.911166. PMID: 30645211; PMCID: PMC6342059.
- [31] Cho ES, Jang YJ, Hwang MK, Kang NJ, Lee KW, Lee HJ. Attenuation of oxidative neuronal cell death by coffee phenolic phytochemicals. *Mutat Res*. 2009;661(1-2):18-24. Doi: 10.1016/j.mrfmmm.2008.10.021. Epub 2008 Nov 5. PMID: 19028509.
- [32] Teraoka M, Nakaso K, Kusumoto C, Katano S, Tajima N, Yamashita A, et al. Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells. *J Clin Biochem Nutr*. 2012;51(2):122-27. Doi: 10.3164/jcbn.D-11-00030. Epub 2012 Apr 6. PMID: 22962530; PMCID: PMC3432822.
- [33] He CL, Tang Y, Wu JM, Long T, Yu L, Teng JF, et al. Chlorogenic acid delays the progression of Parkinson's disease via autophagy induction in *Caenorhabditis elegans*. *Nutr Neurosci*. 2023;26(1):11-24. Doi: 10.1080/1028415X.2021.2009993. Epub 2021 Dec 19. PMID: 34927571.
- [34] Zeng L, Xiang R, Fu C, Qu Z, Liu C. The regulatory effect of chlorogenic acid on gut-brain function and its mechanism: A systematic review. *Biomed Pharmacother*. 2022;149:112831. Doi: 10.1016/j.biopha.2022.112831. Epub 2022 Mar 15. PMID: 35303566.
- [35] Cropley V, Croft R, Silber B, Neale C, Scholey A, Stough C, et al. Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study. *Psychopharmacology (Berl)*. 2012;219(3):737-49. Doi: 10.1007/s00213-011-2395-0. Epub 2011 Jul 20. PMID: 21773723.
- [36] Camfield DA, Silber BY, Scholey AB, Nolidin K, Goh A, Stough C. A randomised placebo-controlled trial to differentiate the acute cognitive and mood effects of chlorogenic acid from decaffeinated coffee. *PLoS One*. 2013;8(12):e82897. Doi: 10.1371/journal.pone.0082897. PMID: 24349389; PMCID: PMC3857311.
- [37] Lardeau A, Poquet L. Phenolic acid metabolites derived from coffee consumption are unlikely to cross the blood-brain barrier. *J Pharm Biomed Anal*. 2013;76:134-38. Doi: 10.1016/j.jpba.2012.12.016. Epub 2012 Dec 21. PMID: 23313775.
- [38] Kumar G, Palival P, Mukherjee S, Patnaik N, Krishnamurthy S, Patnaik R. Pharmacokinetics and brain penetration study of chlorogenic acid in rats. *Xenobiotica*. 2019;49(3):339-45. Doi: 10.1080/00498254.2018.1445882. Epub 2018 Mar 21. PMID: 29480050.

PARTICULARS OF CONTRIBUTORS:

1. Postgraduate Student, Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
2. Assistant Professor, Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
3. Associate Professor, Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
4. Professor and Head, Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Kranthi Karunai Kadal,

Assistant Professor, Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), No. 1, Ramachandra Nagar, Porur, Chennai-600116, Tamil Nadu, India.

E-mail: kranthi@sriramachandra.edu.in

PLAGIARISM CHECKING METHODS: [\[Jain H et al.\]](#)

- Plagiarism X-checker: Mar 01, 2025
- Manual Googling: Apr 22, 2025
- iThenticate Software: Apr 24, 2025 (11%)

ETYMOLOGY: Author Origin

EMENDATIONS: 6

AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? No
- For any images presented appropriate consent has been obtained from the subjects. NA

Date of Submission: [Feb 26, 2025](#)

Date of Peer Review: [Mar 15, 2025](#)

Date of Acceptance: [Apr 26, 2025](#)

Date of Publishing: [Jun 01, 2025](#)